Fill/finish services set to grow at annual rate of over 10%

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Z Wei)
(Image: Getty/Z Wei)

Related tags: fill/finish, Wacker Biotech, Fujifilm diosynth biotechnologies

Growing demand for biologic fill/finish services will see the market develop at a fast pace moving toward 2030, with a number of companies investing heavily in the area.

The contract services market for biologic fill/finish will be worth $4.2bn (€3.7bn) by 2030, a report​ from Roots Analysis suggests.

According to the analysis, the high costs of development, complex production protocols and equipment demands for fill/finish operations means that companies producing biologics often use contract services at this stage of manufacture.

At this stage of the process, after both upstream and downstream processing has been complete, the product is at its most valuable and therefore mistakes in fill/finish can be costly.

This has seen over 115 companies worldwide set up or expand to offer fill/finish services, and little consolidation has been seen in the market, with 40% of those in the industry being identified as mid-sized businesses.

Current annual contract capacity is estimated to be 4.5 billion unit, in terms of packaging containers, and more than 40 million liters, in terms of fill volume.

However, this looks set to increase quickly, with those in the market investing in boosting capacity​, including at the larger end​ of the contract development and manufacturing organization (CDMO) market.

This has contributed to Roots Analysis predicting that, through to 2030, the market will experience a compound annual growth rate (CAGR) of 11.5%.

Another contributing factor to such growth is the wider development of the biologics space, which has companies with traditional focuses elsewhere​ looking to invest.

The report notes one area that is likely to change alongside the development of the biologics industry, which could be a shift away from fill/finish into vials.

Although this is currently the dominant receptacle for biologics, the report notes that its discussions with industry experts suggests that there will be a pivot towards self-administration devices in the future.

Related news

Show more

Related products

show more

High-Density Vero Cell Perfusion Culture

High-Density Vero Cell Perfusion Culture

Eppendorf for Bioprocess – Solutions that grow with you | 01-May-2018 | Application Note

Viral diseases like rabies, rotavirus and influenza are causing many deaths worldwide, resulting in a strong demand for more productive manufacturing techniques...

Related suppliers

Follow us

Products

View more

Webinars